

# CITATION REPORT

List of articles citing

## Sildenafil for pulmonary arterial hypertension: still waiting for evidence

DOI: 10.1164/rccm.2310007

American Journal of Respiratory and Critical Care  
Medicine, 2004, 169, 6-7.

**Source:** <https://exaly.com/paper-pdf/36535298/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Idiopathic- and scleroderma-related pulmonary arterial hypertension: outcomes and QOL on bosentan. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2004</b> , 4, 505-13	2.2	1
19	Corticosteroid resistance in smokers with asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2004</b> , 169, 1252; author reply 1252-3	10.2	9
18	Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon?. <i>Molecular Pharmacology</i> , <b>2004</b> , 66, 11-3	4.3	23
17	[Pulmonary hypertension: from genetics to treatments]. <i>Revue De Pneumologie Clinique</i> , <b>2004</b> , 60, 196-201		4
16	Treatment of pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 1425-36	59.2	1338
15	Sildenafil: emerging cardiovascular indications. <i>Annals of Thoracic Surgery</i> , <b>2004</b> , 78, 1496-506	2.7	53
14	Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease. <i>Pediatric Cardiology</i> , <b>2005</b> , 26, 787-91	2.1	15
13	Clinical response to sildenafil in pulmonary hypertension associated with Gaucher disease. <i>Journal of Inherited Metabolic Disease</i> , <b>2005</b> , 28, 603-5	5.4	11
12	Bosentan therapy for pulmonary arterial hypertension. <i>Future Cardiology</i> , <b>2005</b> , 1, 299-309	1.3	3
11	Pulmonary arterial hypertension associated to connective tissue diseases. <i>Lupus</i> , <b>2005</b> , 14, 713-7	2.6	81
10	Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. <i>European Journal of Clinical Investigation</i> , <b>2006</b> , 36 Suppl 3, 49-53	4.6	35
9	Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension. <i>Scandinavian Journal of Immunology</i> , <b>2006</b> , 64, 69-76	3.4	47
8	Connective tissue associated pulmonary arterial hypertension. <i>Lupus</i> , <b>2006</b> , 15, 138-42	2.6	32
7	Expert opinion on available options treating pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 2247-65	4	30
6	L'hypertension artérielle pulmonaire : stratégies thérapeutiques actuelles. <i>Pharmacien Hospitalier</i> , <b>2008</b> , 43, 35-47		
5	Current and future therapy for pulmonary hypertension in patients with right and left heart failure. <i>Expert Review of Cardiovascular Therapy</i> , <b>2010</b> , 8, 241-50	2.5	2
4	Sildenafil in pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2004</b> , 169, 1256; author reply 1256-7	10.2	

- 3 Tratamento da hipertens arterial pulmonar. *Jornal Brasileiro De Pneumologia*, **2005**, 31, S17-S23 1.1 0
- 2 Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Special Cases?. **2009**, 305-314
- 1 High-altitude Hypoxia Influences the Activities of the Drug-Metabolizing Enzyme CYP3A1 and the Pharmacokinetics of Four Cardiovascular System Drugs. **2022**, 15, 1303 0